2 results
Approved WMORecruiting
The overall aim of this study is to demonstrate increase of tumor-infiltrating CD8+ T cells in non-small cell lung cancer during neo-adjuvant treatment with durvalumab (MEDI4736).
Approved WMOSuspended
The primary objective of the study is survival on a Carmat device at 180 days post-implant* or survival to cardiac transplantation if occurring before 180 days post-implant**. * The beginning of the implant procedure is defined as the start of theā¦